Recommendation ID
NG122/2
Question

What is the effectiveness and cost effectiveness of stereotactic ablative radiotherapy (SABR) compared with surgery (for example, sublobar, wedge resection, lobectomy) for people with non-small-cell lung cancer (stage I and IIA) in whom surgery is suitable?

Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance
Lung cancer: diagnosis and management
Number
NG122
Date issued
March 2019

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 28/03/2019